Blue Horseshoe Stocks: CNDO Recap & Much More

Esperion Therapeutics, Inc. ESPR

ESPR was an unstoppable juggernaut for us this week. On Tuesday, we floated the idea of tracking the ESPR 04/17 $90 Calls, and those contracts have gone on a wild run since then.

As the stock pushed its way to new 52-week highs yesterday, finally topped those contracts out at 28.50, it marked an overall increase of 714% from the 3.50 low we observed on Tuesday; quite an impressive feat for a span of just three sessions.

Add in the multiplicity of opportunities in short-term weekly calls that we’ve witnessed (on the order of percentage gains in the thousands!) as the stock made this historical run, and we’ll have to mark ESPR down as one of our most successful alerts thus far in 2015.


Coronado BioSciences, Inc. CNDO

CNDO did quite well following our tag of it in yesterday morning’s extended watchlist, further solidifying the notion that biopharmas have been on a real hot streak this week.

We watched as CNDO ripped its way from a daily low of 3.62 to as high as 5.35, totaling an intraday run of 48% The move came on volume which smashed the 3-month average by a factor of more than 32X Congrats to any of our readers who lassoed this momentum-mover for some tidy gains yesterday!


Amicus Therapeutics, Inc. FOLD

FOLD also appear on yesterday’s watchlist before extending its own epic run with a modest yet notable increase of 13% on the day, trading a range from 11.63-13.20. Like the previously mentioned play, this stock has also been on a blue-sky breakout, setting new annual highs with every uptick.


Morning Gappers – Options Ideas

Nike, Inc. NKE shares surged as the company beat Wall St. estimates for profits on yesterday’s earnings call, and appears to be gapping up significantly in this morning’s premaket activity. We are going to be monitoring the $101-104 Weekly Calls for potential daytrading opportunities, and for a possible a swing trade into the weeks ahead, we’ll radar the 04/10 $105-110 Calls.

Prothena Corp plc PRTA is gapping up monstrously today to the tune of 40%, soaring on yesterday’s post-market revelation of positive Phase 1 results for its treatment for Parkinson’s disease. We will be placing $35 and 40 Calls on watch for daytrading potential, while tracking the 06/19 $45 Calls for a longer-term play.


Extended Watchlist:
VBLT, SPEX, VGGL, ICLD, RNN